Overview of Dr. Efstathiou
Dr. Eleni Efstathiou is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital and University of Texas M.D. Anderson Cancer Center. She received her medical degree from University of Athens and has been in practice 18 years. She is one of 408 doctors at University of Texas M.D. Anderson Cancer Center and one of 90 doctors at Houston Methodist Hospital who specialize in Oncology. She has more than 100 publications and over 500 citings.
Office
6445 Main Street
Floor 24
Houston, TX 77030
Education & Training
University of AthensClass of 1998
Certifications & Licensure
TX State Medical License 2019 - 2024
OK State Medical License 2020 - 2021
Clinical Trials
- Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer Start of enrollment: 2015 Oct 29
- Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer Start of enrollment: 2017 Oct 13
- Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2018 Mar 06
- Join now to see all
Publications & Presentations
PubMed
- The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a Prostatectomy Pati...Sajeev Sridhar, Zeyad Abouelfetouh, Ion Codreanu, Nakul Gupta, Shu Zhang
The Prostate. 2025-04-01 - The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study: Cabazitaxel...Michalis Liontos, Anna Goussia, Nikolaos Korfiatis, Kyriaki Papadopoulou, Georgios Kanellis
Clinical Genitourinary Cancer. 2025-02-01 - 9 citationsManagement of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi
European Urology. 2025-02-01
Authored Content
- M0 CPRC: Overview of Treatment Options APCCC 2022 Presentation Eleni EfstathiouAugust 2022
Press Mentions
Niraparib and Abiraterone Combination Is Beneficial in Prostate CancerMarch 20th, 2023- Latest in Hormone Sensitive Prostate CancerFebruary 18th, 2023
- Niraparib Improves rPFS in BRCA-Mutated Metastatic Castration-Resistant Prostate CancerFebruary 17th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
